Drug discovery software developer Optibrium has launched version 6.5 of StarDrop™ which provides a complete platform for the design, optimisation and data analysis of small molecules. The latest release introduces WhichP450, a new feature in StarDrop’s P450 metabolism module that predicts which human cytochrome P450 enzymes are the major metabolising isoforms for a novel compound. Understanding how a compound is metabolised enables identification and analysis of its potential metabolites and guides the design of molecules with a reduced risk of drug-drug interactions or variations in exposure across the patient population.
Also included in the latest version of StarDrop is novel R-group clipping functionality that quickly transforms chemical building blocks into their corresponding substituents for enumeration of virtual libraries and the exploration of new compound ideas. Associated data, such as inventory and cost for each building block, are linked with the enumerated compounds to facilitate ordering for synthesis of the best compounds.
The new features have been introduced in parallel with an enhanced data visualisation environment offering more chart types, additional formatting options and a streamlined user interface, enabling publication-quality graphics to be created in a few clicks. This is teamed with a new ‘dashboard’ capability, combining multiple interactive plots in a configurable project view, enabling scientists, team leaders and managers to track the progress of a project at a glance.
For further information about Optibrium and StarDrop visit www.optibrium.com
- Optibrium appoints Clare Devlin as financial director
- Optibrium and University of Nottingham collaborate on innovative teaching programme
- Optibrium and Enamine collaboration extends access to StarDrop commercial compound database
- Optibrium joins eTRANSAFE data standardisation project
- Optibrium, Imperial College and DNDi collaborate on drug development for neglected diseases
- Optibrium and Lhasa Limited in research and product development collaboration
- Molecular design specialist Optibrium appoints Zastra Innovations as software distributor in India
- Optibrium and eMolecules collaborate on data integration for pharmaceutical chemistry research
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!